Neuren Pharmaceuticals has announced it will begin paying dividends to shareholders for the first time after a sharp increase in royalty income from the Rett syndrome treatment DAYBUE (trofinetide). …
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 Australian Biotech
Latest Video
New Stories
-
Most Australians want PBS medicine prices frozen or cut, poll finds
October 30, 2026 - - Latest News -
Canberra program shows young women where a future in health could take them
October 30, 2026 - - Latest News -
If only these patients needed a Spoodle, rather than a medicine
October 30, 2026 - - Latest News -
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News